Published in Am J Psychiatry on February 01, 1995
Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs. Br J Clin Pharmacol (2002) 1.52
A one-year prospective study of the safety, tolerability and pharmacokinetics of the highest available dose of paliperidone palmitate in patients with schizophrenia. BMC Psychiatry (2012) 1.02
Dose-finding study of paliperidone ER based on striatal and extrastriatal dopamine D2 receptor occupancy in patients with schizophrenia. Psychopharmacology (Berl) (2007) 0.95
Plasma concentrations of haloperidol are related to CYP2D6 genotype at low, but not high doses of haloperidol in Korean schizophrenic patients. Br J Clin Pharmacol (2001) 0.86
Dual-isotope SPECT imaging of striatal dopamine: a comparative study between never-treated and haloperidol-treated first-episode schizophrenic patients. Eur Arch Psychiatry Clin Neurosci (2011) 0.81
Randomized, placebo-controlled, double-blind study assessing the efficacy and safety of paliperidone palmitate in Asian patients with schizophrenia. Neuropsychiatr Dis Treat (2013) 0.79
The recognition and optimal management of early psychosis: an evidence-based reform. World Psychiatry (2002) 0.79
A Post-hoc comparison of paliperidone palmitate to oral risperidone during initiation of long-acting risperidone injection in patients with acute schizophrenia. Innov Clin Neurosci (2011) 0.79
Signalling profile differences: paliperidone versus risperidone. Br J Pharmacol (2013) 0.79
Antipsychotic dosing: found in translation. J Psychiatry Neurosci (2014) 0.79
Failure to respond to treatment with typical antipsychotics is not associated with CYP2D6 ultrarapid hydroxylation. Br J Clin Pharmacol (1999) 0.77
NeuN(+) neuronal nuclei in non-human primate prefrontal cortex and subcortical white matter after clozapine exposure. Schizophr Res (2016) 0.75
D2-dopamine-receptor occupancy during treatment with haloperidol decanoate. Eur Arch Psychiatry Clin Neurosci (1997) 0.75
Disassociation between debrisoquine hydroxylation phenotype and genotype among Chinese. Lancet (1989) 2.96
Polymorphisms in the dopamine D2 receptor gene and their relationships to striatal dopamine receptor density of healthy volunteers. Mol Psychiatry (1999) 2.90
Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. Arch Gen Psychiatry (1992) 2.84
Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists. Ann Rheum Dis (2005) 2.46
Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists. Ann Rheum Dis (2005) 2.43
Polymorphic oxidation of sparteine and debrisoquine: related pharmacogenetic entities. Clin Pharmacol Ther (1982) 2.26
Age-related cognitive deficits mediated by changes in the striatal dopamine system. Am J Psychiatry (2000) 2.12
Genetic analysis of the Chinese cytochrome P4502D locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation. Mol Pharmacol (1994) 2.09
Chemical brain anatomy in schizophrenia. Lancet (1995) 2.08
Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. Proc Natl Acad Sci U S A (1993) 2.08
Molecular basis for rational megaprescribing in ultrarapid hydroxylators of debrisoquine. Lancet (1993) 1.87
D1, D2, and 5-HT2 receptor occupancy in relation to clozapine serum concentration: a PET study of schizophrenic patients. Am J Psychiatry (1995) 1.80
EANM procedure guidelines for brain tumour imaging using labelled amino acid analogues. Eur J Nucl Med Mol Imaging (2006) 1.79
Imaging the function of P-glycoprotein with radiotracers: pharmacokinetics and in vivo applications. Clin Pharmacol Ther (2009) 1.77
10-Hydroxylation of nortriptyline in white persons with 0, 1, 2, 3, and 13 functional CYP2D6 genes. Clin Pharmacol Ther (1998) 1.72
Age-related dopamine D2/D3 receptor loss in extrastriatal regions of the human brain. Neurobiol Aging (2000) 1.71
Kinetic analysis of central [11C]raclopride binding to D2-dopamine receptors studied by PET--a comparison to the equilibrium analysis. J Cereb Blood Flow Metab (1989) 1.71
Quantitative analysis of D2 dopamine receptor binding in the living human brain by PET. Science (1986) 1.70
Anti-tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: relative risks and time trends in the Swedish Biologics Register. Ann Rheum Dis (2008) 1.69
No elevated D2 dopamine receptors in neuroleptic-naive schizophrenic patients revealed by positron emission tomography and [11C]N-methylspiperone. Psychiatry Res (1995) 1.66
Validation of methods for CYP2C9 genotyping: frequencies of mutant alleles in a Swedish population. Biochem Biophys Res Commun (1999) 1.66
Clinical pharmacokinetics and pharmacological effects of carbamazepine and carbamazepine-10,11-epoxide. An update. Clin Pharmacokinet (1986) 1.63
Debrisoquine hydroxylation polymorphism and personality. Lancet (1989) 1.62
Plasma kinetics of carbamazepine and its epoxide metabolite in man after single and multiple doses. Eur J Clin Pharmacol (1975) 1.60
CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages. Acta Psychiatr Scand (2001) 1.59
Antiepileptic drugs increase plasma levels of 4beta-hydroxycholesterol in humans: evidence for involvement of cytochrome p450 3A4. J Biol Chem (2001) 1.57
Measurement of striatal and extrastriatal dopamine D1 receptor binding potential with [11C]NNC 112 in humans: validation and reproducibility. J Cereb Blood Flow Metab (2000) 1.56
Pharmacogenetic covariation of defective N-oxidation of sparteine and 4-hydroxylation of debrisoquine. Eur J Clin Pharmacol (1980) 1.55
Monoamine metabolites in CSF and suicidal behavior. Arch Gen Psychiatry (1981) 1.52
Frequent distribution of ultrarapid metabolizers of debrisoquine in an ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles. J Pharmacol Exp Ther (1996) 1.51
Slow omeprazole metabolizers are also poor S-mephenytoin hydroxylators. Ther Drug Monit (1990) 1.50
No support for regional selectivity in clozapine-treated patients: a PET study with [(11)C]raclopride and [(11)C]FLB 457. Am J Psychiatry (2001) 1.49
Why are diazepam metabolism and polymorphic S-mephenytoin hydroxylation associated with each other in white and Korean populations but not in Chinese populations? Clin Pharmacol Ther (1993) 1.46
Low frequency of slow debrisoquine hydroxylation in a native Chinese population. Lancet (1987) 1.42
Clinical pharmacokinetics of carbamazepine. Clin Pharmacokinet (1978) 1.42
D2 dopamine receptors in neuroleptic-naive schizophrenic patients. A positron emission tomography study with [11C]raclopride. Arch Gen Psychiatry (1990) 1.42
Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: a double-blind PET study of schizophrenic patients. Biol Psychiatry (1993) 1.41
S-mephenytoin hydroxylation phenotypes in a Swedish population determined after coadministration with debrisoquin. Clin Pharmacol Ther (1989) 1.41
E- and Z-10-hydroxylation of nortriptyline: relationship to polymorphic debrisoquine hydroxylation. Clin Pharmacol Ther (1981) 1.41
A pharmacometric model describing the relationship between warfarin dose and INR response with respect to variations in CYP2C9, VKORC1, and age. Clin Pharmacol Ther (2010) 1.38
Debrisoquin and mephenytoin hydroxylation phenotypes and CYP2D6 genotype in patients treated with neuroleptic and antidepressant agents. Clin Pharmacol Ther (1993) 1.38
Preparation of a potential positron emission tomographic radioligand for the dopamine transporter. Eur J Nucl Med (1994) 1.38
Central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs. Arch Gen Psychiatry (1988) 1.38
Distribution of D1- and D2-dopamine receptors, and dopamine and its metabolites in the human brain. Neuropsychopharmacology (1994) 1.38
Polymorphic debrisoquin hydroxylation in 757 Swedish subjects. Clin Pharmacol Ther (1988) 1.37
Pharmacokinetics of indomethacin. Clin Pharmacol Ther (1975) 1.31
Cytochrome P450 induction by rifampicin in healthy subjects: determination using the Karolinska cocktail and the endogenous CYP3A4 marker 4beta-hydroxycholesterol. Clin Pharmacol Ther (2008) 1.29
Limbic reductions of 5-HT1A receptor binding in human temporal lobe epilepsy. Neurology (2004) 1.28
Interphenotype differences in disposition and effect on gastrin levels of omeprazole--suitability of omeprazole as a probe for CYP2C19. Br J Clin Pharmacol (1995) 1.28
Indole-3-acetic acid in human cerebrospinal fluid: identification and quantification by mass fragmentography. Science (1972) 1.27
Methylation of mercury compounds by methylcobalamin. Biochemistry (1971) 1.27
Autoradiographic localization of 5-HT1A receptors in the post-mortem human brain using [3H]WAY-100635 and [11C]way-100635. Brain Res (1997) 1.26
A novel mutant variant of the CYP2D6 gene (CYP2D6*17) common in a black African population: association with diminished debrisoquine hydroxylase activity. Br J Clin Pharmacol (1996) 1.26
Comparison of the transient equilibrium and continuous infusion method for quantitative PET analysis of [11C]raclopride binding. J Cereb Blood Flow Metab (1998) 1.25
"Serotonin depression"--a biochemical subgroup within the affective disorders? Science (1976) 1.24
Role of CYP2C9 polymorphism in losartan oxidation. Drug Metab Dispos (2001) 1.23
Imaging the living human brain: magnetic resonance imaging and positron emission tomography. Proc Natl Acad Sci U S A (1997) 1.22
Quantification of [11C]FLB 457 binding to extrastriatal dopamine receptors in the human brain. J Cereb Blood Flow Metab (1999) 1.22
Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis. J Pharmacol Exp Ther (1995) 1.21
Pharmacokinetics and biological effects of nortriptyline in man. Acta Pharmacol Toxicol (Copenh) (1971) 1.21
Antipyrine metabolism in relation to polymorphic oxidations of sparteine and debrisoquine. Br J Clin Pharmacol (1983) 1.21
Distribution and elimination kinetics of carbamazepine in man. Eur J Clin Pharmacol (1975) 1.20
Synthesis of L- and D-[methyl-11C]methionine. J Nucl Med (1987) 1.20
Extensive metabolizers of debrisoquine become poor metabolizers during quinidine treatment. Pharmacol Toxicol (1987) 1.20
Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians: comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype. Pharmacogenetics (1995) 1.20
Reduced dopamine transporter binding in patients with juvenile myoclonic epilepsy. Neurology (2008) 1.20
Carbon-11-FLB 457: a radioligand for extrastriatal D2 dopamine receptors. J Nucl Med (1995) 1.18
PCR-based genotyping for duplicated and deleted CYP2D6 genes. Pharmacogenetics (1996) 1.17
Genetic polymorphism of cytochrome P450 2C9 in a Caucasian and a black African population. Br J Clin Pharmacol (2001) 1.17
Genetically variable metabolism of antidepressants and neuroleptic drugs in man. Pharmacogenetics (1993) 1.16
Polymorphic hydroxylation of S-mephenytoin and omeprazole metabolism in Caucasian and Chinese subjects. Pharmacogenetics (1992) 1.16
Reproducibility of [11 C]FLB 457 binding in extrastriatal regions. Nucl Med Commun (2001) 1.16
Effect of rifampicin and CYP2B6 genotype on long-term efavirenz autoinduction and plasma exposure in HIV patients with or without tuberculosis. Clin Pharmacol Ther (2011) 1.15
Cognitive deficits in Huntington's disease are predicted by dopaminergic PET markers and brain volumes. Brain (1997) 1.15
Slow hydroxylation of nortriptyline and concomitant poor debrisoquine hydroxylation: clinical implications. Lancet (1981) 1.14
Results from a nationwide postmarketing cohort study of patients in Sweden treated with etanercept. Ann Rheum Dis (2004) 1.14
Regional cerebral oxidative and total glucose consumption during rest and activation studied with positron emission tomography. Acta Physiol Scand (1994) 1.13
Nortriptyline and antipyrine clearance in relation to debrisoquine hydroxylation in man. Life Sci (1980) 1.13
Transplantation in Parkinson's disease: two cases of adrenal medullary grafts to the putamen. Ann Neurol (1987) 1.13
Bantu Tanzanians have a decreased capacity to metabolize omeprazole and mephenytoin in relation to their CYP2C19 genotype. Clin Pharmacol Ther (1998) 1.12
PET study of the pre- and post-synaptic dopaminergic markers for the neurodegenerative process in Huntington's disease. Brain (1997) 1.12